関連する実験動画
Updated: May 5, 2026

09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
14.4K
プラバスタチンによる脳卒中の減少:将来的なプラバスタチンプーリング (PPP) プロジェクト
R P Byington1, B R Davis, J F Plehn
1Wake Forest University School of Medicine, Winston-Salem, NC 27157-1063, USA. bbyingto@wfubmc.edu
Circulation
|February 7, 2001
まとめ
プラバスタチンは,冠動脈疾患の患者の脳卒中リスクを有意に低下させ,主に非致命的,非出血性脳卒中を減少させました. この発見は,この集団における脳卒中予防のためのスタチンの使用を支持しています.
科学分野:
- 心血管医学 心血管医学
- 神経学 神経学とは
- 薬理学 薬理学とは
背景:
- 脳卒中は死亡と障害の主な原因です.
- 以前の脂質低下療法では,脳卒中の減少は示されなかった.
- 最近のスタチンの治験は,脳卒中予防の潜在的な利点を示唆しています.
研究 の 目的:
- プラバスタチンが脳卒中に及ぼす効果を評価する.
- 大規模なプラセボ対照試験から集約されたデータを分析する.
- 二次性脳卒中予防におけるプラヴァスタチンの有効性を決定する.
主な方法:
- 3つのランダム化,プラセボ対照試験のプール分析.
- 19,768人の患者が含まれて,102,559人年経過の追跡調査が行われました.
- 約5年間の脳卒中事件を調査した.
主要な成果:
- CAREとLIPIDの試験を組み合わせた分析では,全脳卒中の22%の減少 (P=0.01) が示されました.
- プラバスタチンは,非致死性脳卒中を25% (95%CI 10%から38%) 減少させた.
- 非出血性脳卒中の23%の減少が観察され,出血性脳卒中の違いは認められなかった.
結論:
- プラバスタチンは,冠動脈疾患の患者の様々な脂質レベルにおいて,脳卒中リスクを効果的に軽減しました.
- この利点は,非致命的,非出血性脳卒中の減少に起因する.
- プラバスタチンは,二次脳卒中予防に重要な役割を果たしていることを示しています.
関連する概念動画
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
